BrainStorm Cell Therapeutics (NASDAQ:BCLI) traded higher in the premarket Tuesday after announcing that the U.S. FDA has endorsed the design of a late-stage trial for its cell therapy candidate NurOwn...
Source LinkBrainStorm Cell Therapeutics (NASDAQ:BCLI) traded higher in the premarket Tuesday after announcing that the U.S. FDA has endorsed the design of a late-stage trial for its cell therapy candidate NurOwn...
Source Link
Comments